Poster Hall
Sponsored by AbbVie Medical Affairs
Conference Perspectives
View all perspectives
Janet Pope Janetbirdope
3 months 1 week ago
#EULAR2024 #scleroderma #recommend’ns @eular_org
#lung #ILD
Divide in to
#prevention vs #Rx
#Immune #suppressive #Rx vs
#antifibrotic
My thoughts -?other Rx as ⬆️MR
Likely all effective early #Rx of skin
Improve Risk of
#progression▶️ILD
@EUSTAR_org @RheumNow https://t.co/4wJyeSEHv3
Peter Nash drpnash
3 months 1 week ago
EFFICACY AND SAFETY OF IXEKIZUMAB IN CHILDREN WITH ACTIVE JUVENILE PSORIATIC ARTHRITIS AND ENTHESITIS RELATED ARTHRITIS (COSPIRIT-JIA): 16-WEEK RESULTS OF A MULTICENTRE, RANDOMISED, OPEN-LABEL STUDY - IL17 effective & safe in JIA @RheumNow #EULAR2024
Aurelie Najm AurelieRheumo
3 months 1 week ago
Izokibep Ph2b/3 RCT PsA 340+
Primary endpoint ACR50 wk 16
IZO 160 mg Q2W 43%
IZO 160 mg QW 40%
PBO 15%
Effect early as wk 4
PASI100
IZO Q2W 47%
IZO QW 51%
PBO 12%
Safety profile similar to IL-17i
@RheumNow #EULAR2024 LBA0005 https://t.co/vWRQ1ECrAX
Aurelie Najm AurelieRheumo
3 months 1 week ago
ReMonit RCT 240+ axSPA pts
Remote Monitoring & Patient-initiated Care NON INFERIOR Usual care for ASDAS <2.1 over 18mo
No diff between Patient-initiated Care & Remote Monitoring
No diff in disease activity & function
>90% satisfaction in all arms
#EULAR2024 @RheumNow LB0004 https://t.co/mLTS5fLXFN
David Liew drdavidliew
3 months 1 week ago
This is critical.
If we're going to try and treat pre-RA, it's all about picking the right patient:
- avoid exposing future non-responders to harm
- modify the course of disease in those who will benefit
Fantastic that @eular_org are addressing this need.
#EULAR2024 @RheumNow https://t.co/9pF33eLbuZ
David Liew drdavidliew
3 months 1 week ago
Scleroderma: the present, and the future.
#EULAR2024 @RheumNow https://t.co/v5vxfmM4i3
Aurelie Najm AurelieRheumo
3 months 1 week ago
Open-label extension of BE MOBILE 2 Ph3 Bimekizumab in r-axSpA
200 pts w/ 2yr radiographic outcome
85.3% non progressors (mSASSS CfB ≤0.5) 92.1% (mSASSS CfB <2)
83.1% had existing structural damage (mSASSS ≥2) at BL
#EULAR2024 @RheumNow Abst LBA0003 https://t.co/DQeiXHDnSF
Aurelie Najm AurelieRheumo
3 months 1 week ago
PRO-SPIRIT 1100+ PsA Observational study
IXE i= TNFi and JAKi for improving joint dis activity in IXE higher previous b/tsDMARD & less concomitant csDMARDs
IXE & IL-17Ai = faster improvement cDAPSA than IL-12/23i or IL-23i
Abst LBA0002 #EULAR2024 @RheumNow https://t.co/8DbtCQECNN
Aurelie Najm AurelieRheumo
3 months 1 week ago
IL-6 Immunotherapy for knee OA PPV-06 FTIH Phase 1
Is it safe? looks it, no serious AES, 6mo follow up
Is it immunogenic? apparently so, IL-6 Ab & neutralizing Ab
Does it work? will have to wait for Phase 2
Somehow bold knowing TCZ did not work in hand OA
AbstLBA0011 #EULAR2024… https://t.co/pO0Dx3jl8E https://t.co/p1zYUtgFoM
Janet Pope Janetbirdope
3 months 1 week ago
#Scleroderma updated #EULAR2024
#recommendations @eular_org
SKIN
Are they good enough?
Great work by task force @EUSTAR_org
Do we alter initial Rx if v high mRSS?
Ex #MMF not much improvement on skin vs #RTX #Cyclo
Or combo Rx?
We need to improve #SoC
?CAR-T ? RCT
@RheumNow https://t.co/WhEzDdjVeu
Janet Pope Janetbirdope
3 months 1 week ago
#Scleroderma updated #EULAR2024
#recommendations @eular_org
Are they good enough?
Great work by task force @EUSTAR_org
#PAH my thoughts
Where does #sotaracept in #PAH fit in
Not mentioned
?#selexipag before #epoprostenol
For sure there is country variant
@RheumNow https://t.co/3dJ6eusSkU
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 1 week ago
#EULAR2024 LBA0001 New Steroid-sparring therapy for #GCA. Phase 3 RCT showed Upadacitinib 15mg met primary endpoint (sustained clin remission frm Wks 12-52 & adherence to 26Wk GC taper) vs PBO [46% vs 29%] & multiple secondary endpoints. No new safety signals @RheumNow https://t.co/edfSZkMuy2
Mrinalini Dey DrMiniDey
3 months 1 week ago
LBA0001 UPA in GCA- Phase 2 RCT
15mg UPA with 26w steroid taper showed
⬆️ efficacy
⬇️ steroid use
vs placebo with 52w steroid taper
Potential new target on the horizon for #GCA??
@RheumNow #EULAR2024
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 1 week ago
#EULAR2024 POS0417 Using EXPLORE Inflammation I & II proteomics, marked immune dysregulation was seen in new ANA+ referral vs HC. 34% progressed to #lupus & #Sjogren. Six potential baseline biomarkers identified & closely resembled established SLE. Validation is ongoing @RheumNow https://t.co/I6HygqNwf7
David Liew drdavidliew
3 months 1 week ago
Nipocalimab (anti-FcRn - i.e. PLEX-in-a-bottle) with a positive phase 2 in Sjogren’s.
This study is in high systemic dx pts (with nice response matching biological plausibility) - but salivary flow improved too
ESSPRI didn’t quite make it, but close #EULAR2024 LBA0010 @RheumNow https://t.co/PslFKJBOOr
